Goldman Sachs initiated coverage on Krystal Biotech Inc. (NASDAQ:KRYS) with a Buy rating.
The investment bank established a price target of $441.00 for the stock.
Analysts identified Krystal Biotech as a profitable, commercial-stage leader in gene therapy for rare diseases.
The company maintains gross profit margins of 95% and demonstrates successful commercial execution.
Goldman Sachs noted that the broader biotechnology sector remains resilient despite economic headwinds.
Sector momentum continues to be driven by increased acquisition activity and promising clinical trial results.